Clinicians who routinely manage patients screened for lung cancer with low-dose CT have a new 1-page printout to illuminate evidence-based care pathways when faced with significant but questionably urgent incidental findings.

An AI startup has been cleared to market a platform for precisely mapping prostate cancer with 3D visualization so the tumor can be treated without harm to healthy surrounding prostate tissue.

According to data submitted to the FDA, the platform has been linked to an accuracy of 90%, sensitivity of 87.8% and specificity of 83%.

Ed Gaines, JD, vice president of regulatory affairs and industry liaison, Zotec Partners, discussed the impact of the 2023 Medicare Fee Schedule on radiology at RSNA 2022 in Chicago last week. RSNA and several other medical societies say the cuts are not sustainable.